Abstract
Cell proliferation, survival, differentiation, migration and metabolism are some of the fundamental cellular processes tightly controlled by the activity of tyrosine-kinase receptors (RTKs). The aberrant signaling of RTKs contributes to cancer growth and survival and has become important target for therapeutic approaches. Well-characterized kinase molecular target in lung cancer, in particular in non-small cell lung cancer (NSCLC), is the activated epidermal growth factor receptor (EGFR) pathway. More recently, the oncogenic role of other two tyrosine-kinases, the hepatocyte growth factor receptor (MET) and the anaplastic lymphoma kinase (ALK), has been recognized. Many different therapeutic strategies have been investigated with the goal to inhibit these receptors, subsequent downstream signaling cascades and arrest tumor growth. This review will discuss the MET and ALK pathways, the different strategies of their inhibition and the potential approaches to overcome acquired resistance to kinase inhibitors in these two genes.
Current Pharmaceutical Design
Title:MET and ALK as Targets for the Treatment of NSCLC
Volume: 20 Issue: 24
Author(s): Capelletti M, Gelsomino F. and Tiseo M.
Affiliation:
Abstract: Cell proliferation, survival, differentiation, migration and metabolism are some of the fundamental cellular processes tightly controlled by the activity of tyrosine-kinase receptors (RTKs). The aberrant signaling of RTKs contributes to cancer growth and survival and has become important target for therapeutic approaches. Well-characterized kinase molecular target in lung cancer, in particular in non-small cell lung cancer (NSCLC), is the activated epidermal growth factor receptor (EGFR) pathway. More recently, the oncogenic role of other two tyrosine-kinases, the hepatocyte growth factor receptor (MET) and the anaplastic lymphoma kinase (ALK), has been recognized. Many different therapeutic strategies have been investigated with the goal to inhibit these receptors, subsequent downstream signaling cascades and arrest tumor growth. This review will discuss the MET and ALK pathways, the different strategies of their inhibition and the potential approaches to overcome acquired resistance to kinase inhibitors in these two genes.
Export Options
About this article
Cite this article as:
M Capelletti, F. Gelsomino and M. Tiseo, MET and ALK as Targets for the Treatment of NSCLC, Current Pharmaceutical Design 2014; 20 (24) . https://dx.doi.org/10.2174/13816128113196660760
DOI https://dx.doi.org/10.2174/13816128113196660760 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in the Treatment of Interstitial Lung Disease in Patients with Polymyositis/Dermatomyositis
Endocrine, Metabolic & Immune Disorders - Drug Targets Prostaglandin J2 Family and the Cardiovascular System
Current Vascular Pharmacology Enrichment of Up-regulated and Down-regulated Gene Clusters Using Gene Ontology, miRNAs and lncRNAs in Colorectal Cancer
Combinatorial Chemistry & High Throughput Screening Modulation of pRb/E2F Functions in the Regulation of Cell Cycle and in Cancer
Current Cancer Drug Targets Curcumin and Lung Cancer: the Role of microRNAs
Current Pharmaceutical Design The Endocannabinoid System in the Cancer Therapy: An Overview
Current Medicinal Chemistry Evidence for Extensive Non-Endocytotic Translocation of Peptide Nucleic Acids Across Mammalian Plasma Membranes
Current Drug Delivery P-Glycoprotein, but not Multidrug Resistance Protein 4, Plays a Role in the Systemic Clearance of Irinotecan and SN-38 in Mice
Drug Metabolism Letters Genetics and Genomics Interventions for Promoting Millets as Functional Foods
Current Genomics Genistein: A Boon for Mitigating Ischemic Stroke
Current Topics in Medicinal Chemistry MicroRNAs in Skin Response to UV Radiation
Current Drug Targets Histone Methyltransferase Inhibitors: Novel Epigenetic Agents for Cancer Treatment
Current Medicinal Chemistry The use of nanocarriers in acute myeloid leukaemia therapy: challenges and current status.
Current Pharmaceutical Biotechnology Ganoderma lucidum (Ling-zhi): The Impact of Chemistry on Biological Activity in Cancer
Current Bioactive Compounds Pentacyclic Triterpenoids and Their Saponins with Apoptosis-Inducing Activity
Current Topics in Medicinal Chemistry Smart Drug Release Systems Based on Stimuli-Responsive Polymers
Mini-Reviews in Medicinal Chemistry Small Molecule Kinase Inhibitors as Anti-Cancer Therapeutics
Mini-Reviews in Medicinal Chemistry Airway Smooth Muscle Responsiveness: The Origin of Airway Hyperresponsiveness in Asthma?
Current Respiratory Medicine Reviews Semaphorins and their Receptors in Stem and Cancer Cells
Current Medicinal Chemistry DNA Damage-inducing Compounds: Unraveling their Pleiotropic Effects Using High Throughput Sequencing
Current Medicinal Chemistry